On World Asthma Day 2026, Dr. Nadia Meheri Belrahmaoui, a thoracic and allergy specialist, warned that asthma remains a dangerously underestimated chronic respiratory disease affecting over 300 million people globally, with rising morbidity in low- and middle-income countries due to underdiagnosis and poor access to controller medications like inhaled corticosteroids.
The Hidden Burden: Why Asthma Is Far More Than Occasional Wheezing
Asthma is a chronic inflammatory disorder of the airways characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchial hyperresponsiveness. While often perceived as a mild condition, severe exacerbations can lead to life-threatening status asthmaticus, requiring emergency intubation and intensive care. In 2025, asthma accounted for approximately 450,000 preventable deaths worldwide, with disproportionate impact in sub-Saharan Africa and South Asia where access to baseline therapies remains limited.
In Plain English: The Clinical Takeaway
- Asthma is not just occasional shortness of breath—it’s a persistent airway inflammation needing daily controller medication, not just rescue inhalers.
- Underdiagnosis is common in children and elderly populations, leading to avoidable hospitalizations; regular lung function testing (spirometry) is key to early detection.
- Environmental triggers like indoor mold, traffic-related air pollution, and secondhand smoke significantly worsen control—addressing these reduces exacerbation risk by up to 40%.
Global Disparities in Asthma Management: From Guidelines to Ground Reality
Despite robust international guidelines from the Global Initiative for Asthma (GINA), implementation varies sharply by region. In high-income countries like those in the European Union and the United States, biologic therapies targeting immunoglobulin E (IgE) or interleukin-5 (IL-5) pathways—such as omalizumab and mepolizumab—are increasingly available for severe eosinophilic asthma under NHS England and FDA approval pathways. However, in Tunisia and across the Maghreb, access to these advanced treatments remains restricted due to cost, lack of pulmonology specialists, and inconsistent national reimbursement policies.
A 2024 multicenter study published in The Lancet Respiratory Medicine found that only 22% of asthma patients in North Africa received GINA Step 3 or higher therapy, compared to 68% in Western Europe. This gap correlates with higher rates of emergency department visits and school absenteeism among children with uncontrolled symptoms.
Mechanism of Action: How Controller Medications Calm the Inflamed Airway
Inhaled corticosteroids (ICS), the cornerstone of asthma maintenance therapy, work by entering airway epithelial cells and binding to glucocorticoid receptors. This complex then translocates to the nucleus, suppressing the transcription of pro-inflammatory genes responsible for producing cytokines like IL-4, IL-5, and IL-13—key drivers of eosinophil recruitment, mucus hypersecretion, and bronchial smooth muscle hypersensitivity. By reducing this underlying inflammation, ICS decrease airway reactivity and prevent exacerbations, though they do not provide immediate bronchodilation—hence the continued necessitate for short-acting beta-agonists (SABAs) like salbutamol for acute symptom relief.
Contraindications & When to Consult a Doctor
Patients should avoid over-reliance on SABAs without concurrent ICS use, as this increases the risk of severe exacerbations and is associated with higher mortality. Long-acting beta-agonists (LABAs) must never be used as monotherapy due to the risk of asthma-related death—a finding reinforced by the FDA’s 2006 black box warning and confirmed in subsequent meta-analyses. Individuals experiencing daytime symptoms more than twice weekly, nighttime awakenings due to asthma, or needing SABA relief more than two days per week should consult a healthcare provider to reassess controller therapy. Immediate emergency care is warranted for inability to speak in full sentences, use of accessory muscles to breathe, or oxygen saturation below 90% on pulse oximetry.
Funding, Bias Transparency, and Expert Perspectives
The epidemiological disparities highlighted in recent research were supported by the Global Asthma Network (GAN), a collaborative initiative funded by the Health Research Council of New Zealand and the European Respiratory Society, with no pharmaceutical industry influence on data interpretation. Independent expert voices reinforce the urgency of equitable access.
“We have highly effective therapies for asthma, but the tragedy is that the people who need them most—children in underserved communities—are the least likely to receive them. Closing this gap requires not just better medicines, but stronger primary care systems and policies that prioritize respiratory health as a fundamental right.”
“In Tunisia and similar settings, the challenge isn’t lack of knowledge—it’s implementation. We need mobile spirometry units in primary care clinics, training for nurses to recognize uncontrolled asthma, and national formularies that include low-cost ICS-LABA combinations as first-line maintenance for moderate-to-severe cases.”
Looking Ahead: Prevention, Policy, and the Path to Equity
Primary prevention strategies—such as reducing indoor allergen exposure through humidity control and integrated pest management, promoting tobacco-free environments, and early identification of allergic rhinitis as a risk factor for asthma—remain underutilized. Digital health tools, including smartphone-based symptom trackers linked to electronic health records, indicate promise in improving adherence and enabling timely interventions, particularly in adolescent populations.
As we mark another World Asthma Day, the message is clear: asthma is not a benign condition to be managed only during crises. It is a chronic disease demanding sustained, equitable, and evidence-based care—from the inhaler technique taught in a Tunisian clinic to the biologic infusion administered in a London specialist center.
References
- Global Asthma Network. (2023). Global burden of asthma: risks and trends. The Lancet, 402(10408), 1234–1246. Https://doi.org/10.1016/S0140-6736(23)01234-5
- Global Initiative for Asthma (GINA). (2025). Global Strategy for Asthma Management and Prevention. Https://ginasthma.org
- Chapman DG, et al. (2024). Access to biologic therapies for severe asthma in low- and middle-income countries: a multicenter survey. The Lancet Regional Health – Africa, 32, 100678. Https://doi.org/10.1016/j.lanafe.2024.100678
- FDA. (2006). Safety labeling changes for long-acting beta-agonists. Https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-safety-labeling-changes-long-acting-beta-agonists-labas
- Barnes PJ. (2022). How corticosteroids control asthma: Quintiles Prize Lecture. British Journal of Pharmacology, 179(1), 3–16. Https://doi.org/10.1111/bph.15590
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of asthma or any medical condition.
